How to Be a Member ?

1 Fill the membership application form.
2Provide professional references from two society members.
3Send the original signed document with 2 passport photographs to us.

For your questions, suggestions, and requests, send an e-mail to info@trsgo.org Thank you!

INTERNATIONAL CLINICAL TRIALS

IMagyn050/GOG 3015/ENGOT-OV39

A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer.

Principal Investigator: Dr. Çağatay Taşkıran

Centers:
1- Koç University Faculty of Medicine
2- Istanbul University Cerrahpasa Faculty of Medicine
3- Istanbul University Istanbul Faculty of Medicine
4- Ankara University Faculty of Medicine
5- Baskent University Faculty of Medicine - Ankara
6- Baskent University Faculty of Medicine - Adana

Patient Selection: Completed

DUO-O/ENGOT-ov46/AGO

A phase III randomised, double-blind, placebo-controlled, multicentre study of Durvalumab in combination with chemotherapy and Bevacizumab, followed by maintenance Durvalumab, Bevacizumab and Olaparib in newly diagnosed advanced ovarian cancer patients (DUO-O).

Principal Investigator: Dr. Mehmet Ali Vardar

Centers:
1- Çukurova University Faculty of Medicine - Adana
2- Baskent University Faculty of Medicine - Ankara
3- Hacettepe University Faculty of Medicine
4- Ege University Faculty of Medicine
5- Bezmialem Vakıf University Faculty of Medicine
6- Memorial Şişli Hospital İstanbul

Patient Selection: Continuing

ATHENA /ENGOT-ov45/NCRI

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy

Principal Investigator: Dr. Fuat Demirkıran

Centers:
1- Istanbul University Cerrahpasa Faculty of Medicine
2- Ankara Oncology Training and Research Hospital
3- Celal Bayar University Faculty of Medicine
4- Gazi University Faculty of Medicine
5- Baskent University Faculty of Medicine - Adana
6- Koç University Faculty of Medicine

Patient Selection: Continuing

ENGOT-ov43/BGOG

Randomized phase III first line study in ovarian cancer comparing paclitaxel carboplatinum, with paclitaxel/carboplatin and pembrolizumab and olaparib

Principal Investigator: Dr. Samet Topuz

Centers:
1- Istanbul University Istanbul Faculty of Medicine
2- Akdeniz University Faculty of Medicine
3- Acıbadem University Faculty of Medicine -Atakent Hospital
4- Etlik Zübeyde Hanım Women Health Training and Research Hospital
5- Uludağ University Faculty of Medicine
6- Ankara University Faculty of Medicine
7- Sakarya Training and Research Hospital
8- İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital

Patient Selection: Continuing

ENGOT-en9/A-AGO/LEAP-001

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Principal Investigator: Dr. Ali Ayhan

Centers:
1- Baskent University Faculty of Medicine - Ankara
2- Çukurova University Faculty of Medicine - Adana
3- Baskent University Faculty of Medicine - Adana
4- Gazi University Faculty of Medicine
5- Uludağ University Faculty of Medicine
6- Akdeniz University Faculty of Medicine

Patient Selection: Continuing

ENGOT-cx13/AGO/FERMATA

An international randomized double-blind clinical trial of BCD-100 plus platinum-based chemotherapy with and without Bevacizumab versus placebo plus platinum-based chemotherapy with and without Bevacizumab as first-line treatment of subjects with advanced cervical cancer

Principal Investigator: Dr. Coşan Terek

Centers:
1- Ege University Faculty of Medicine
2- Baskent University Faculty of Medicine - Adana
3- Istanbul University Istanbul Faculty of Medicine
4- Çukurova University Faculty of Medicine - Adana
5- Ankara University Faculty of Medicine
6- Ankara Oncology Training and Research Hospital

Patient Selection: Continuing

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11)

Case groups included in this prospective multicenter study

  • 1. FIGO 2014 stage IB2-IIB pelvic and / or paraortic node positive cases
  • 2. FIGO 2014 stage III-IVA cases (Node positive or negative)

The aim of the study is to investigate the effect of Pembrolizumab addition to standard primary chemoradiation therapy on disease-free survival and survival in cervix cancer.

Not: Note: Evaluation of lymphatic spread can be done by surgery or imaging, and details of the study can be obtained from the relevant centers.

Principal Investigator: Dr. Ali Ayhan

Centers:
1- Başkent University Faculty of Medicine Ankara
2- İstanbul University Cerrahpasa Faculty of Medicine
3- Adana Acıbadem Hospital
4- Koç University Faculty of Medicine

Patient Selection: Continuing

PS: New trials to be opened will be published as soon as possible.

Sadece üyelerin erişebilecekleri alanları görmek için giriş yapın.

ÜYE OL

ŞİFRENİ Mİ UNUTTUN ?

YUKARI